Abstract
SCD1 inhibition may represent a novel treatment for obesity, type-2 diabetes and related metabolic disorders. A prototype thiazole amide analog 13 (MF-152) was identified as an excellent tool in the study of SCD biology in animals.
MeSH terms
-
Administration, Oral
-
Animals
-
Cell Line, Tumor
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacology
-
Humans
-
Hypoglycemic Agents / chemical synthesis
-
Hypoglycemic Agents / chemistry*
-
Hypoglycemic Agents / pharmacology
-
Mice
-
Mice, Inbred C57BL
-
Mice, Knockout
-
Piperazines / chemical synthesis
-
Piperazines / chemistry*
-
Piperazines / pharmacology
-
Rats
-
Stearoyl-CoA Desaturase / antagonists & inhibitors*
-
Stearoyl-CoA Desaturase / metabolism
-
Thiazoles / chemical synthesis
-
Thiazoles / chemistry*
-
Thiazoles / pharmacology
Substances
-
Enzyme Inhibitors
-
Hypoglycemic Agents
-
MF 152
-
Piperazines
-
Thiazoles
-
Stearoyl-CoA Desaturase